## BEAM: Beam Therapeutics Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.8% below STRENGTH zone (3.0-6.0%); PEG 7.09 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($24.92)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Beam Therapeutics (BEAM) Is Up 9.9% After BEACON Data Boosts Confidence In Risto-cel Therapy**
- Source: Simply Wall Street | 20251225T140928 | Bullish | Relevance: 100%
- Beam Therapeutics saw a 9.9% stock increase following promising BEACON trial data for its risto-cel therapy, which proposes an innovative treatment for sickle cell disease. H.C. Wainwright analyst Patrick Trucchio reaffirmed a positive view, noting Beam's strong manufacturing process and the FDA's RMAT designation for BEAM 101, which could streamline regulatory processes. While the data strengthens the clinical profile for sickle cell disease as a central value driver, the company still faces risks related to safety and funding.

**2. Beam Therapeutics (BEAM) Is Up 9.9% After BEACON Data Boosts Confidence In Risto-cel Therapy**
- Source: Simply Wall Street | 20251225T000907 | Bullish | Relevance: 100%
- Beam Therapeutics (BEAM) stock surged 9.9% following encouraging BEACON trial data for risto-cel, a potential sickle cell disease treatment. H.C. Wainwright analyst Patrick Trucchio reaffirmed a positive view, highlighting the therapy's innovative potential and Beam's differentiated manufacturing process. This data, coupled with an FDA RMAT designation, strengthens Beam's investment narrative around sickle cell disease, though safety and conditioning risks still exist.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.02M) |
| Sells | 5 ($0.65M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 2 |

**Top Holders:**
- FMR, LLC: 11.5% (-9.8%)
- ARK Investment Manag: 10.9% (+24.8%)
- Farallon Capital Man: 9.9% (+0.5%)
- Vanguard Group Inc: 9.1% (-4.7%)
- Blackrock Inc.: 8.0% (+1.8%)

### Key Risks

1. High beta (2.22) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Valuation stretched: PEG 7.1x requires aggressive growth execution.
3. High short interest (21.9%, 10.2 days to cover): squeeze risk or crowded bearish bet.

### Catalysts

- Momentum building: MRS_10 improving +2.7% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 7.09 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (6.0x), low leverage (D/E 0.36). Revenue growth strong at 22% YoY. Institutional flow bullish (6 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.8B |
| Beta | 2.22 |
| 52W Range | $13.53 - $35.25 |
| Short Interest | 21.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 7.09 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from -0.9% to 1.8% (+2.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.2pp (needs >3.0% for momentum thesis). MRS_5 at 0.7% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 60. OFD pattern: -DLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.76% (CS: 93) | Neutral |
| RSI_14 | 59.8 | Neutral |
| MACD Histogram | 0.07 | Bullish |
| vs SMA20 | 1.046x | Above |
| vs SMA50 | 1.107x | Above |
| vs SMA200 | 1.332x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $27.98
- **Stop Loss:** $24.92 (10.9% risk)
- **Target:** $31.04 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 431
- **Position Value:** $12,059.38
- **Portfolio %:** 12.06%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-24 (Est: $-1.12)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.01 | $-1.10 | -8.9% |
| 2025Q2 | $-1.09 | $-1.00 | +8.4% |
| 2025Q1 | $-1.17 | $-1.24 | -5.9% |
| 2024Q4 | $-1.22 | $-1.09 | +10.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*